Purpose: To investigate the efficacy of intraarterial administration of tirofiban for stroke treatment beyond the conventional window period and evaluate its impact on prognosis.Methods: A retrospective study was conducted on ninety (90) acute ischemic stroke patients admitted to The First Affiliated Hospital of Hainan Medical University, Haikou, China from July 2021 to October 2022. The patients were divided into Tirofiban group (50) and non-Tirofiban group (40) based on whether the patients received arterial clopidogrel. National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) and Barthel index (BI) scores were used to evaluate adverse drug reactions and its impact on prognosis for patients with symptoms onset within 6 - 24 h.Results: No significant differences were observed between the groups in terms of age, gender, medical history, personal history, blood indicators and neurologic function scores (p > 0.05). The median NIHSS score on admission and after 24 h of treatment was 4 in both groups and 3 in both groups after 72 h of treatment. However, after 7 days of treatment, the median NIHSS score was lower in Tirofiban group (2.0) than in non-Tirofiban group (2.5; p > 0.05). Tirofiban group demonstrated higher rates of effective treatment and good prognosis compared to non-Tirofiban group. Importantly, there was no significant difference in the occurrence of adverse reactions between the two groups (p > 0.05).Conclusion: Tirofiban, given via the arteries, improves neurological functions following hyper-acute stroke even beyond the window period and without adverse reactions. It is a safe and effective antiplatelet drug for late-life treatment. For future studies, it will be necessary to broaden the treatment scope and gather more robust and reliable data in order to enhance data quality.
{"title":"Safety and efficacy of arterial injection of tirofiban in treating ischemic stroke beyond the window period","authors":"Qiongwen Rong, Fenglei Chen, Yuanyuan Ma, Yi Cai","doi":"10.4314/tjpr.v22i9.28","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.28","url":null,"abstract":"Purpose: To investigate the efficacy of intraarterial administration of tirofiban for stroke treatment beyond the conventional window period and evaluate its impact on prognosis.Methods: A retrospective study was conducted on ninety (90) acute ischemic stroke patients admitted to The First Affiliated Hospital of Hainan Medical University, Haikou, China from July 2021 to October 2022. The patients were divided into Tirofiban group (50) and non-Tirofiban group (40) based on whether the patients received arterial clopidogrel. National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) and Barthel index (BI) scores were used to evaluate adverse drug reactions and its impact on prognosis for patients with symptoms onset within 6 - 24 h.Results: No significant differences were observed between the groups in terms of age, gender, medical history, personal history, blood indicators and neurologic function scores (p > 0.05). The median NIHSS score on admission and after 24 h of treatment was 4 in both groups and 3 in both groups after 72 h of treatment. However, after 7 days of treatment, the median NIHSS score was lower in Tirofiban group (2.0) than in non-Tirofiban group (2.5; p > 0.05). Tirofiban group demonstrated higher rates of effective treatment and good prognosis compared to non-Tirofiban group. Importantly, there was no significant difference in the occurrence of adverse reactions between the two groups (p > 0.05).Conclusion: Tirofiban, given via the arteries, improves neurological functions following hyper-acute stroke even beyond the window period and without adverse reactions. It is a safe and effective antiplatelet drug for late-life treatment. For future studies, it will be necessary to broaden the treatment scope and gather more robust and reliable data in order to enhance data quality.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"162 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135251666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To determine the underlying mechanisms of action of Astragalus membranaceus in lumbar disc herniation (LDH) treatment.Methods: This study utilized network pharmacology analysis and STRING database to identify compound targets and visualize PPI network. Furthermore, an LDH model was induced in human nucleus pulposus cells using lipopolysaccharide (LPS), and then the vital target genes were evaluated in this model treated with active components of Astragalus membranaceus.Results: Network pharmacology analysis indicates that several key proteins, including vascular endothelial growth factor A (VEGF A), AKT1, JUN, prostaglandin-endoperoxide synthase 2 (PTGS2), interleukin-6 (IL-6), matrix metallopeptidase 9 (MMP9), interleukin-1β (IL-1β), C-X-C motif chemokine ligand 8 (CXCL8), epidermal growth factor (EGF) and matrix metallopeptidase 2 (MMP2) may play essential roles in LDH treated with Astragalus membranaceus. The active components in Astragalus membranaceus suppressed the production of IL-1β and IL-6, and increased the expressions of VEGF A, MMP9 and MMP2 in LPS-induced LDH model.Conclusion: The active components of Astragalus membranaceus effectively inhibits inflammation in LPS-induced LDH model, indicating that Astragalus membranaceus is a potential therapeutic candidate for LDH treatment.
{"title":"Investigation of the mechanism of <i>Astragalus membranaceus</i> in the treatment of lumbar disc herniation using network pharmacology","authors":"WenJie Ke, Chengwei Yu, Wei Liu, Haifeng Liu","doi":"10.4314/tjpr.v22i9.7","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.7","url":null,"abstract":"Purpose: To determine the underlying mechanisms of action of Astragalus membranaceus in lumbar disc herniation (LDH) treatment.Methods: This study utilized network pharmacology analysis and STRING database to identify compound targets and visualize PPI network. Furthermore, an LDH model was induced in human nucleus pulposus cells using lipopolysaccharide (LPS), and then the vital target genes were evaluated in this model treated with active components of Astragalus membranaceus.Results: Network pharmacology analysis indicates that several key proteins, including vascular endothelial growth factor A (VEGF A), AKT1, JUN, prostaglandin-endoperoxide synthase 2 (PTGS2), interleukin-6 (IL-6), matrix metallopeptidase 9 (MMP9), interleukin-1β (IL-1β), C-X-C motif chemokine ligand 8 (CXCL8), epidermal growth factor (EGF) and matrix metallopeptidase 2 (MMP2) may play essential roles in LDH treated with Astragalus membranaceus. The active components in Astragalus membranaceus suppressed the production of IL-1β and IL-6, and increased the expressions of VEGF A, MMP9 and MMP2 in LPS-induced LDH model.Conclusion: The active components of Astragalus membranaceus effectively inhibits inflammation in LPS-induced LDH model, indicating that Astragalus membranaceus is a potential therapeutic candidate for LDH treatment.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135250936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiayu Lu, Taihao Cui, Zhaoxiang Yu, Wei Zheng, Wei He
Purpose: To investigate analgesic effect and safety of dexmedetomidine combined with ropivacaine in ultrasound-guided brachial plexus block in intercostal space.Methods: A total of 90 patients were scheduled to undergo upper limb surgery and divided into control and study groups, respectively. Patients in control group were given ropivacaine nerve block, while those in study group were given ropivacaine combined with dexmedetomidine mixture nerve block. The efficiency of sensory and motor block, secondary evaluation of block effect, visual analogue scale (VAS) scores at different postoperative moments, remedial analgesia and adverse reactions were compared between the two groups after 30 min of drug injection.Results: The success rate of sensory block was not significantly different between control group (91.11 %) and study group (93.33 %; χ2 = 0.155, p > 0.05) but success rate of the motor block was significantly higher in study group (93.33 %) than in control group (71.11 %; χ2 = 7.601, p < 0.05). Compared with control group, onset of sensory block and motor block were significantly shorter in study group, while the duration of sensory block and motor block was significantly longer (p < 0.05). The VAS scores at 12, 24, and 48 h postoperatively were significantly lower in study group than control group (p < 0.05). The number of self-administered analgesia, number of patients, dose used, and overall incidence of adverse reactions in study group were significantly lower than in control group (p < 0.05).Conclusion: Dexmedetomidine and ropivacaine, when administered together, have a significant anesthetic effect during nerve block, which is safe and enhances their analgesic effect. However, the mechanism of improving analgesic effect of the combined plan, using a larger number of samples should be further investigated.
目的:探讨右美托咪定联合罗哌卡因在超声引导下肋间隙臂丛阻滞中的镇痛效果及安全性。方法:90例患者计划行上肢手术，分为对照组和研究组。对照组患者给予罗哌卡因神经阻滞，研究组患者给予罗哌卡因联合右美托咪定混合物神经阻滞。比较两组患者术后不同时刻的感觉和运动阻滞效率、阻滞效果二次评价、视觉模拟评分(VAS)评分、药物注射30 min后的补救镇痛及不良反应。结果:对照组(91.11%)与研究组(93.33%)感觉阻滞成功率无显著差异;χ2 = 0.155, p >0.05)，但运动阻滞成功率(93.33%)明显高于对照组(71.11%);χ2 = 7.601, p <0.05)。与对照组比较，研究组感觉阻滞和运动阻滞的发作时间显著缩短，而感觉阻滞和运动阻滞的持续时间显著延长(p <0.05)。研究组术后12、24、48 h VAS评分均显著低于对照组(p <0.05)。研究组自我镇痛次数、患者数量、使用剂量、不良反应总发生率均显著低于对照组(p <0.05)。结论:右美托咪定与罗哌卡因联用在神经阻滞过程中具有明显的麻醉作用，安全且能增强镇痛效果。然而，联合方案提高镇痛效果的机制，使用更大的样本量还有待进一步研究。
{"title":"Analgesic and safety analysis of dexmedetomidine combined with ropivacaine in ultrasound-guided brachial plexus nerve block","authors":"Jiayu Lu, Taihao Cui, Zhaoxiang Yu, Wei Zheng, Wei He","doi":"10.4314/tjpr.v22i9.21","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.21","url":null,"abstract":"Purpose: To investigate analgesic effect and safety of dexmedetomidine combined with ropivacaine in ultrasound-guided brachial plexus block in intercostal space.Methods: A total of 90 patients were scheduled to undergo upper limb surgery and divided into control and study groups, respectively. Patients in control group were given ropivacaine nerve block, while those in study group were given ropivacaine combined with dexmedetomidine mixture nerve block. The efficiency of sensory and motor block, secondary evaluation of block effect, visual analogue scale (VAS) scores at different postoperative moments, remedial analgesia and adverse reactions were compared between the two groups after 30 min of drug injection.Results: The success rate of sensory block was not significantly different between control group (91.11 %) and study group (93.33 %; χ2 = 0.155, p > 0.05) but success rate of the motor block was significantly higher in study group (93.33 %) than in control group (71.11 %; χ2 = 7.601, p < 0.05). Compared with control group, onset of sensory block and motor block were significantly shorter in study group, while the duration of sensory block and motor block was significantly longer (p < 0.05). The VAS scores at 12, 24, and 48 h postoperatively were significantly lower in study group than control group (p < 0.05). The number of self-administered analgesia, number of patients, dose used, and overall incidence of adverse reactions in study group were significantly lower than in control group (p < 0.05).Conclusion: Dexmedetomidine and ropivacaine, when administered together, have a significant anesthetic effect during nerve block, which is safe and enhances their analgesic effect. However, the mechanism of improving analgesic effect of the combined plan, using a larger number of samples should be further investigated.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135250940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the potential role of osmidrosis lotion in alleviating axillary osmidrosis (AO).Methods: Forty patients were randomly divided into four groups (n = 10). Patients were treated via topical application of Lithargyrum, Sophora flavescens Alt., or Cortex dictamni, or osmidrosis lotion, for 40 min over a three-month period. Total skin RNA was extracted from samples using TRIzol while total platelet RNA was treated with DNase I, followed by quantification using NanoDrop and Agilent 2100 Bioanalyzer.Results: Lithargyrum, Sophora flavescens Alt. and Cortex dictamni significantly inhibited the mRNA expressions of ApoD and ABCC11 in AO patients (p < 0.05). Furthermore, osmidrosis lotion produced the best down-regulating effect on mRNA expressions of ApoD and ABCC11 in AO patients.Conclusion: The suppressive effect of these natural remedies may be beneficial in the development of non-surgical therapy for AO and therefore would be worth further investigation.
{"title":"Osmidrosis lotion affect ApoD and ABCC11 mRNA levels in axillary osmidrosis patients","authors":"Bin Chen, JiFeng Xie, KeKe Ding, ChunRong Gong","doi":"10.4314/tjpr.v22i9.16","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.16","url":null,"abstract":"Purpose: To investigate the potential role of osmidrosis lotion in alleviating axillary osmidrosis (AO).Methods: Forty patients were randomly divided into four groups (n = 10). Patients were treated via topical application of Lithargyrum, Sophora flavescens Alt., or Cortex dictamni, or osmidrosis lotion, for 40 min over a three-month period. Total skin RNA was extracted from samples using TRIzol while total platelet RNA was treated with DNase I, followed by quantification using NanoDrop and Agilent 2100 Bioanalyzer.Results: Lithargyrum, Sophora flavescens Alt. and Cortex dictamni significantly inhibited the mRNA expressions of ApoD and ABCC11 in AO patients (p < 0.05). Furthermore, osmidrosis lotion produced the best down-regulating effect on mRNA expressions of ApoD and ABCC11 in AO patients.Conclusion: The suppressive effect of these natural remedies may be beneficial in the development of non-surgical therapy for AO and therefore would be worth further investigation.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135250948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To determine the efficacy and safety of irbesartan plus calcitriol in the treatment of IgA nephropathy, and its effect on inflammatory injury and complement systemMethods: Differences in renal function, inflammatory response, immune function, complement factor levels, clinical efficacy, and incidence of adverse reactions between IgA nephropathy patients treated with irbesartan (control, n = 50) and those treated with irbesartan + calcitriol (study group, n = 50) after 2 and 12 months, were retrospectively analyzed. As treatment progressed, protein in 24-h urine, and creatinine and BUN in both groups were gradually reduced.Results: The serum levels of complement factors C1q and C3 in both groups gradually increased, while C4 level gradually decreased. Relative to pre-treatment, at 2- and 12-months post-treatment, serum levels of C1q and C3 in both groups were raised, while C4 level decreased (p < 0.05). Relative to control, serum C1q and C3 in the study group were raised, while C4 level was decreased (p < 0.05). Relative to the control group, total treatment effectiveness in the study group increased at 2- and 12- months post-treatment (p < 0.05). There was no significant difference in the incidence of adverse reactions between the control and study groups during the treatment.Conclusion: Treatment with irbesartan + calcitriol significantly improves renal function in patients with IgA nephropathy, reduces inflammatory response, and improves immune function and clinical effectiveness with high safety profile. More clinical trials should be carried out to validate the findings of this study.
{"title":"Short-term and long-term efficacies of combined use of irbesartan and calcitriol for the treatment of IgA nephropathy","authors":"Laming Li, Laming Li, Yan Jiang","doi":"10.4314/tjpr.v22i9.19","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.19","url":null,"abstract":"Purpose: To determine the efficacy and safety of irbesartan plus calcitriol in the treatment of IgA nephropathy, and its effect on inflammatory injury and complement systemMethods: Differences in renal function, inflammatory response, immune function, complement factor levels, clinical efficacy, and incidence of adverse reactions between IgA nephropathy patients treated with irbesartan (control, n = 50) and those treated with irbesartan + calcitriol (study group, n = 50) after 2 and 12 months, were retrospectively analyzed. As treatment progressed, protein in 24-h urine, and creatinine and BUN in both groups were gradually reduced.Results: The serum levels of complement factors C1q and C3 in both groups gradually increased, while C4 level gradually decreased. Relative to pre-treatment, at 2- and 12-months post-treatment, serum levels of C1q and C3 in both groups were raised, while C4 level decreased (p < 0.05). Relative to control, serum C1q and C3 in the study group were raised, while C4 level was decreased (p < 0.05). Relative to the control group, total treatment effectiveness in the study group increased at 2- and 12- months post-treatment (p < 0.05). There was no significant difference in the incidence of adverse reactions between the control and study groups during the treatment.Conclusion: Treatment with irbesartan + calcitriol significantly improves renal function in patients with IgA nephropathy, reduces inflammatory response, and improves immune function and clinical effectiveness with high safety profile. More clinical trials should be carried out to validate the findings of this study.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"164 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135251664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the clinical efficacy of Gushukang Jiaonang in the prevention and treatment of osteoporosis, and its effect on patients' bone metabolism based on its use in traditional Chinese medicine.Methods: Retrospective analysis was conducted on 108 patients with osteoporosis discharged from the North Hospital Affiliated Hospital of Gansu University of Traditional Chinese Medicine, from January 2021 to January 2023. Patients were divided into study group (n = 54) and control group (n = 54). Control group received oral calcitriol and calcium tablets, while study group orally received calcitriol and calcium tablets and Gushukang Jiaonang capsules in addition. Clinical symptom improvement scores, bone mineral density, serum phosphorus and calcium, and blood alkaline phosphatase levels were compared between the groups.Results: After treatment, total amino terminal prolonging peptide of collagen I in the blood of study group was significantly higher than before treatment (p < 0.05). Osteocalcin was significantly increased before and after treatment in the two groups (p < 0.05). Vitamin D levels were significantly increased before and after treatment, and the difference was statistically significant (p < 0.05).Conclusion: Gushukang Jiaonang provides patients with efficient, comprehensive and precise prevention and treatment of osteoporosis. It also promotes positive disease regression, which in turn contributes to increase in bone mineral density in individuals. Long-term investigations with a larger population size, more indices as well as multicenter control should be carried out to provide sufficient theoretical basis for use in clinical practice.
{"title":"Clinical efficacy of Gushukang Jiaonang in osteoporosis and its effects on bone metabolism in patients: A retrospective study","authors":"Zengpeng Lu, Zhangkai Zhao, Qibin Sun, Yuping Zhao, Jinyi Li, Xingzhang Yao, Tuanzhuang Zhang","doi":"10.4314/tjpr.v22i9.20","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.20","url":null,"abstract":"Purpose: To investigate the clinical efficacy of Gushukang Jiaonang in the prevention and treatment of osteoporosis, and its effect on patients' bone metabolism based on its use in traditional Chinese medicine.Methods: Retrospective analysis was conducted on 108 patients with osteoporosis discharged from the North Hospital Affiliated Hospital of Gansu University of Traditional Chinese Medicine, from January 2021 to January 2023. Patients were divided into study group (n = 54) and control group (n = 54). Control group received oral calcitriol and calcium tablets, while study group orally received calcitriol and calcium tablets and Gushukang Jiaonang capsules in addition. Clinical symptom improvement scores, bone mineral density, serum phosphorus and calcium, and blood alkaline phosphatase levels were compared between the groups.Results: After treatment, total amino terminal prolonging peptide of collagen I in the blood of study group was significantly higher than before treatment (p < 0.05). Osteocalcin was significantly increased before and after treatment in the two groups (p < 0.05). Vitamin D levels were significantly increased before and after treatment, and the difference was statistically significant (p < 0.05).Conclusion: Gushukang Jiaonang provides patients with efficient, comprehensive and precise prevention and treatment of osteoporosis. It also promotes positive disease regression, which in turn contributes to increase in bone mineral density in individuals. Long-term investigations with a larger population size, more indices as well as multicenter control should be carried out to provide sufficient theoretical basis for use in clinical practice.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"67 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135250938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Huifen Wu, Pengfei Li, Jingying Guan, Jiaxuan Hong
Purpose: To study the effects of Jade Wind-Barrier Powder on peripheral blood interferon-γ (INF-γ), immunoglobulin and sputum mucin in children with asthma.Methods: Sixty-six children with asthma in remission stage were randomly separated into study and control groups. The control group was treated with budesonide formoterol powder inhaler, while the study group was orally administered Jade Wind-Barrier Powder. The therapeutic effects, and INF-γ, immunoglobulin and mucin levels in sputum, as well as pulmonary function parameters in both groups were determined. The number of acute relapses of asthma and duration of wheezing were counted in the patients. The relative effectiveness of Jade Wind-Barrier Powder in the treatment of asthma in the children was also assessed.Results: The overall response rate (ORR) in the study group was 93.94 %, which was higher than in the control group (75.76 %, p < 0.05). Over the 6-month period of follow-up, the frequency of acute attacks of asthma in the study group was significantly lower while the duration of wheezing during attack was also shorter than in the control group. After treatment, pulmonary function indices in the study group were higher, whereas mucin 5AC (MUC5AC), mucin 5B (MUC5B) and mucin 1 (MUC1) levels in sputum were lower than in the control group (p < 0.05).Conclusion: Jade Wind-Barrier Powder exerts therapeutic effect in children with asthma. However, further clinical trials across multi-centers are required to validate it its use in clinical practice.
{"title":"Efficacy of Jade Wind-Barrier Powder in adjuvant treatment for children with asthma, and its influence on IFN-γ, immunoglobulin and mucin","authors":"Huifen Wu, Pengfei Li, Jingying Guan, Jiaxuan Hong","doi":"10.4314/tjpr.v22i9.26","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.26","url":null,"abstract":"Purpose: To study the effects of Jade Wind-Barrier Powder on peripheral blood interferon-γ (INF-γ), immunoglobulin and sputum mucin in children with asthma.Methods: Sixty-six children with asthma in remission stage were randomly separated into study and control groups. The control group was treated with budesonide formoterol powder inhaler, while the study group was orally administered Jade Wind-Barrier Powder. The therapeutic effects, and INF-γ, immunoglobulin and mucin levels in sputum, as well as pulmonary function parameters in both groups were determined. The number of acute relapses of asthma and duration of wheezing were counted in the patients. The relative effectiveness of Jade Wind-Barrier Powder in the treatment of asthma in the children was also assessed.Results: The overall response rate (ORR) in the study group was 93.94 %, which was higher than in the control group (75.76 %, p < 0.05). Over the 6-month period of follow-up, the frequency of acute attacks of asthma in the study group was significantly lower while the duration of wheezing during attack was also shorter than in the control group. After treatment, pulmonary function indices in the study group were higher, whereas mucin 5AC (MUC5AC), mucin 5B (MUC5B) and mucin 1 (MUC1) levels in sputum were lower than in the control group (p < 0.05).Conclusion: Jade Wind-Barrier Powder exerts therapeutic effect in children with asthma. However, further clinical trials across multi-centers are required to validate it its use in clinical practice.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135250941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the effects of amiodarone hydrochloride tablets combined with potassium magnesium aspartate on hemodynamics and cardiac function in coronary heart disease (CHD) patients with arrhythmia.Methods: In this retrospective research, a total of 110 CHD and arrhythmia patients on admission at Jiaozhou Central Hospital of Qingdao from June 2020 to June 2022 were randomly but equally divided into control group (CG) treated with propafenone hydrochloride tablets, and study group (SG) treated with a combination of amiodarone hydrochloride tablets and potassium magnesium aspartate. Clinical efficacy of the treatment types as well as the number of premature ventricular contractions (PVC), QTc interval and heart rate (HR) of the patients were monitored to determine left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and cardiac index (CI). Fibrinogen levels, plasma viscosity and hematocrit of the patients were also assessed.Results: The total effectiveness/efficacy of treatment in SG was 92.73 %, which was significantly higher than the corresponding CG value of 76.36 % (p < 0.05). Relative to CG, PVC and HR in SG were significantly lower, while QTc interval was significantly higher. The levels of LVESD and LVEDD were significantly lower in SG than in CG, while CI level was significantly higher. However, fibrinogen, plasma viscosity and hematocrit values were significantly lower in SG than in CG (p < 0.05).Conclusion: When administered along with potassium magnesium aspartate in the treatment of CHD and arrhythmia, amiodarone hydrochloride tablets enhances clinical efficacy and improves electrocardiograph index, hemodynamics and cardiac function. Nonetheless, there is need for expanded clinical trials before the use of this treatment strategy in clinical practice.
{"title":"Effect of amiodarone hydrochloride tablets combined with potassium magnesium aspartate on hemodynamics and cardiac function in patients with coronary heart disease and arrhythmia","authors":"Gongzhu Han, Hong Qiu, Yichun Mao","doi":"10.4314/tjpr.v22i9.27","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.27","url":null,"abstract":"Purpose: To investigate the effects of amiodarone hydrochloride tablets combined with potassium magnesium aspartate on hemodynamics and cardiac function in coronary heart disease (CHD) patients with arrhythmia.Methods: In this retrospective research, a total of 110 CHD and arrhythmia patients on admission at Jiaozhou Central Hospital of Qingdao from June 2020 to June 2022 were randomly but equally divided into control group (CG) treated with propafenone hydrochloride tablets, and study group (SG) treated with a combination of amiodarone hydrochloride tablets and potassium magnesium aspartate. Clinical efficacy of the treatment types as well as the number of premature ventricular contractions (PVC), QTc interval and heart rate (HR) of the patients were monitored to determine left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and cardiac index (CI). Fibrinogen levels, plasma viscosity and hematocrit of the patients were also assessed.Results: The total effectiveness/efficacy of treatment in SG was 92.73 %, which was significantly higher than the corresponding CG value of 76.36 % (p < 0.05). Relative to CG, PVC and HR in SG were significantly lower, while QTc interval was significantly higher. The levels of LVESD and LVEDD were significantly lower in SG than in CG, while CI level was significantly higher. However, fibrinogen, plasma viscosity and hematocrit values were significantly lower in SG than in CG (p < 0.05).Conclusion: When administered along with potassium magnesium aspartate in the treatment of CHD and arrhythmia, amiodarone hydrochloride tablets enhances clinical efficacy and improves electrocardiograph index, hemodynamics and cardiac function. Nonetheless, there is need for expanded clinical trials before the use of this treatment strategy in clinical practice.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135251112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To determine the cost-effectiveness and efficacy of camrelizumab when combined with radiotherapy in the management of advanced/metastatic esophageal squamous cell carcinoma (ESCC).Methods: A retrospective analysis was carried out on clinical information of 115 patients with advanced/metastatic ESCC admitted to Huai'an Cancer Hospital between February 2017 and January 2021. Based on therapeutic modality, patients were distributed into control group (CG, 55 cases, cisplatin + paclitaxel chemotherapy) and study group (SG, 60 cases, camrelizumab + radiotherapy regimen). Clinical efficacy, adverse effects, cost indicators (total cost of treatment, out-of-pocket costs, medical insurance cost), serum tumor marker levels (CEA, CYFRA21-1, SCC-Ag), immune function (IgA, IgG, IgM), and quality of life were compared between the two groups.Results: The objective remission rate (ORR) in SG (80 %) was significantly higher than in CG (61.8 %) (p < 0.05). Serum levels of CEA, CYFRA21-1, SCC-Ag in both groups and symptom scores decreased, while serum IgA, IgG, IgM, function, and overall quality of life score increased, but the improvement was greater in SG after 6 weeks of treatment (p < 0.05). Study group had significantly higher out-of-pocket expenses, health insurance costs, total costs, and cost/effectiveness than CG (p < 0.05).Conclusion: Camrelizumab combined with radiotherapy in the treatment of advanced/metastatic ESCC is efficacious, improves immune function, reduces serum tumor marker levels, and prolongs the survival time of patients. Clinical studies using larger population should be carried out to validate the findings of this study.
{"title":"Cost-effectiveness analysis of camrelizumab combination with radiotherapy for management of advanced/metastatic esophageal squamous cell carcinoma","authors":"Biwen Sun, Jinghong Liu, Rongrong Ge, Changxiang Luo, Chongyang Zhang","doi":"10.4314/tjpr.v22i9.29","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.29","url":null,"abstract":"Purpose: To determine the cost-effectiveness and efficacy of camrelizumab when combined with radiotherapy in the management of advanced/metastatic esophageal squamous cell carcinoma (ESCC).Methods: A retrospective analysis was carried out on clinical information of 115 patients with advanced/metastatic ESCC admitted to Huai'an Cancer Hospital between February 2017 and January 2021. Based on therapeutic modality, patients were distributed into control group (CG, 55 cases, cisplatin + paclitaxel chemotherapy) and study group (SG, 60 cases, camrelizumab + radiotherapy regimen). Clinical efficacy, adverse effects, cost indicators (total cost of treatment, out-of-pocket costs, medical insurance cost), serum tumor marker levels (CEA, CYFRA21-1, SCC-Ag), immune function (IgA, IgG, IgM), and quality of life were compared between the two groups.Results: The objective remission rate (ORR) in SG (80 %) was significantly higher than in CG (61.8 %) (p < 0.05). Serum levels of CEA, CYFRA21-1, SCC-Ag in both groups and symptom scores decreased, while serum IgA, IgG, IgM, function, and overall quality of life score increased, but the improvement was greater in SG after 6 weeks of treatment (p < 0.05). Study group had significantly higher out-of-pocket expenses, health insurance costs, total costs, and cost/effectiveness than CG (p < 0.05).Conclusion: Camrelizumab combined with radiotherapy in the treatment of advanced/metastatic ESCC is efficacious, improves immune function, reduces serum tumor marker levels, and prolongs the survival time of patients. Clinical studies using larger population should be carried out to validate the findings of this study.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"117 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135251529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To determine the efficacy and safety of Buyang Huanwu Decoction (BHD) + olanzapine in the treatment of vascular dementia (VD) after cerebral ischemic stroke (CIS).Methods: Ninety patients with VD after CIS were assigned to 2 groups: a conventional group treated with olanzapine, and a combination group given olanzapine + BHD. Traditional Chinese medicine (TCM) symptom score was evaluated in each group. Neurological function, degree of dementia, and activities of daily living (ADL) were evaluated using National Institute of Health Stroke Scale (NIHSS), Clinical Dementia Rating (CDR) scale, and ADL scale, respectively. Levels of inflammatory factors, oxidative stress, and neurotrophic factors in peripheral blood were also determined. Middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), and vertebral artery (VA) blood flow velocity (BFV) were assessed. Therapeutic effects and adverse reactions (ARs) were recorded as well.Results: The TCM symptom, NHSS, and CDR scores were decreased in the combination group, while ADL scores were increased (p < 0.05). Levels of hs-CRP, IL-6, and malondialdehyde (MDA) also decreased, while IL-10, GPx, SOD, NT3, MCA, ACA, PVA, and VA BFV, and BDNF levels increased (p < 0.05). Clinical effectiveness (CE) levels in the conventional and combination groups were 73.3 and 93.3 %, while the incidence of ARs were 11.11 and 6.7 %, respectively (p < 0.05).Conclusion: Olanzapine + BHD mitigates clinical symptoms, enhances neurological function, decreases the degree of dementia, and increases ADL in patients with vascular dementia after CIS. Moreover, it improves cerebral blood flow, and it is safe to use. An increase in sample size will be needed to compare the long-term efficacy of olanzapine alone, and that of its combination with BHD in the treatment of VD after CIS.
{"title":"Effect of combined use of Buyang Huanwu decoction and olanzapine on clinical symptoms, neurological function, and degree of dementia in patients with vascular dementia after cerebral ischemic stroke","authors":"Limin Zhang, Di Wu, Nian Chen","doi":"10.4314/tjpr.v22i9.25","DOIUrl":"https://doi.org/10.4314/tjpr.v22i9.25","url":null,"abstract":"Purpose: To determine the efficacy and safety of Buyang Huanwu Decoction (BHD) + olanzapine in the treatment of vascular dementia (VD) after cerebral ischemic stroke (CIS).Methods: Ninety patients with VD after CIS were assigned to 2 groups: a conventional group treated with olanzapine, and a combination group given olanzapine + BHD. Traditional Chinese medicine (TCM) symptom score was evaluated in each group. Neurological function, degree of dementia, and activities of daily living (ADL) were evaluated using National Institute of Health Stroke Scale (NIHSS), Clinical Dementia Rating (CDR) scale, and ADL scale, respectively. Levels of inflammatory factors, oxidative stress, and neurotrophic factors in peripheral blood were also determined. Middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), and vertebral artery (VA) blood flow velocity (BFV) were assessed. Therapeutic effects and adverse reactions (ARs) were recorded as well.Results: The TCM symptom, NHSS, and CDR scores were decreased in the combination group, while ADL scores were increased (p < 0.05). Levels of hs-CRP, IL-6, and malondialdehyde (MDA) also decreased, while IL-10, GPx, SOD, NT3, MCA, ACA, PVA, and VA BFV, and BDNF levels increased (p < 0.05). Clinical effectiveness (CE) levels in the conventional and combination groups were 73.3 and 93.3 %, while the incidence of ARs were 11.11 and 6.7 %, respectively (p < 0.05).Conclusion: Olanzapine + BHD mitigates clinical symptoms, enhances neurological function, decreases the degree of dementia, and increases ADL in patients with vascular dementia after CIS. Moreover, it improves cerebral blood flow, and it is safe to use. An increase in sample size will be needed to compare the long-term efficacy of olanzapine alone, and that of its combination with BHD in the treatment of VD after CIS.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135251532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：